Having demonstrated that NXP800 has growth inhibitory effects in AR-dependent and AR-independent prostate cancer models, we next investigated further the effects of the drug by performing RNA-seq on VCaP, LNCaP95, and 22Rv1 prostate cancer cells subsequent to NXP800 treatment (Fig. 3C–E; Supplementary Tables S7–S9). The gene discussed is AR; the disease is prostate cancer.